## Source (95% CI)

## Sequencing = FPKM

Liu, Melanoma, n = 121 -0.35 [-0.96; 0.26] Nathanson, Melanoma, n = 24 0.04 [-1.14; 1.22] Hugo, Melanoma, n = 27 0.53 [-0.67; 1.73] Total -0.12 [-0.63; 0.38] Heterogeneity:  $\chi^2_2$  = 1.75 (P = .42),  $I^2$  = 0% [0%; 90%]

## Sequencing = TPM

Mariathasan, Kidney, n = 67-0.35 [-0.92; 0.22] -0.13 [-0.82; 0.56] Riaz, Melanoma, n = 51 Miao.1, Kidney, n = 33-0.08 [-1.00; 0.84] Mariathasan, Bladder, n = 1940.09 [-0.20; 0.38] Fumet.2, Lung, n = 430.24 [-0.49; 0.97] Braun, Kidney, n = 1780.26 [-0.15; 0.67] Mariathasan, Ureteral, n = 26 0.31 [-0.59; 1.21] Mariathasan, Lymph\_node,  $n = 26 \ 0.43 \ [-0.37; 1.23]$ Van\_Allen, Melanoma, n = 42 0.75 [-0.15; 1.65] Snyder, Ureteral, n = 250.86 [-0.08; 1.80] 0.15 [-0.03; 0.33] Total Heterogeneity:  $\chi_9^2 = 8.82 \ (P = .45), \ I^2 = 0\% \ [0\%; 62\%]$ 0.11 [-0.06; 0.28] Total Heterogeneity:  $\chi_{12}^2 = 11.66 \ (P = .47), \ I^2 = 0\% \ [0\%; 57\%]$ Test for overall effect:  $z = 1.31 \ (P = .19)$ 

Test for subgroup differences:  $\chi_1^2 = 0.96$  (P = .33)

-0.5 0 0.5 1 logHR estimate